PLx Pharma Operating Income

PLx Pharma posts a operating income of $-40M as of September 2022. That compares with $-24M in the prior-year period — down 69.3% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, PLx Pharma's operating income was $-24M. The latest reading is $-40M — a 69.3% year-over-year decrease (period ending September 2022). Use the history and growth charts on this page for a longer lookback.

Operating Income is one piece of PLx Pharma's financial statement story. At $-40M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for PLXP's operating income usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; PLx Pharma's other metric pages and overview cover the third.

Judging PLx Pharma against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in operating income easier to interpret. Start with $-40M here, then scan peer and history charts to see if the gap is persistent.